Kiniksa Pharmaceuticals Stock Forecast, Price & News

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

Is Kiniksa Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kiniksa Pharmaceuticals stock.
View analyst ratings for Kiniksa Pharmaceuticals or view top-rated stocks.

How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has decreased by 29.8% and is now trading at $11.30.
View which stocks have been most impacted by COVID-19.

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 2,170,000 shares, a decrease of 33.0% from the October 31st total of 3,240,000 shares. Based on an average daily volume of 334,400 shares, the short-interest ratio is presently 6.5 days.
View Kiniksa Pharmaceuticals' Short Interest.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Kiniksa Pharmaceuticals.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings data on Monday, November, 1st. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.21. The business earned $12.10 million during the quarter, compared to the consensus estimate of $9.92 million.
View Kiniksa Pharmaceuticals' earnings history.

What price target have analysts set for KNSA?

2 equities research analysts have issued twelve-month price objectives for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $34.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $29.00 in the next twelve months. This suggests a possible upside of 156.6% from the stock's current price.
View analysts' price targets for Kiniksa Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:

• Sanj K. Patel, Chairman & Chief Executive Officer
• Mark Ragosa, Chief Financial Officer & Senior Vice President
• John F. Paolini, Chief Medical Officer & Senior Vice President
• Dana Martin, Senior VP-Global Medical Affairs
• Ross Moat, Vice President & GM-Rilonacept Franchise

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals CEO Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among Kiniksa Pharmaceuticals' employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Kiniksa Pharmaceuticals' key competitors?

Some companies that are related to Kiniksa Pharmaceuticals include Cytokinetics (CYTK), 23andMe (ME), ACADIA Pharmaceuticals (ACAD), Arcus Biosciences (RCUS), Hypera (HYPMY), Amicus Therapeutics (FOLD), Dicerna Pharmaceuticals (DRNA), Cryoport (CYRX), Prestige Consumer Healthcare (PBH), Schrödinger (SDGR), OPKO Health (OPK), Ligand Pharmaceuticals (LGND), PTC Therapeutics (PTCT), ChemoCentryx (CCXI) and Corcept Therapeutics (CORT).
View all of KNSA's competitors.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.55%), Opaleye Management Inc. (1.91%), ArrowMark Colorado Holdings LLC (1.79%), Hudson Bay Capital Management LP (1.68%), Rice Hall James & Associates LLC (1.08%) and Goldman Sachs Group Inc. (0.71%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends for Kiniksa Pharmaceuticals.

Which major investors are selling Kiniksa Pharmaceuticals stock?

KNSA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Morgan Stanley, Citigroup Inc., Rafferty Asset Management LLC, Citadel Advisors LLC, Los Angeles Capital Management LLC, and New York State Common Retirement Fund. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include Sanj K Patel, and Thomas W Beetham.
View insider buying and selling activity for Kiniksa Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Kiniksa Pharmaceuticals stock?

KNSA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Great Point Partners LLC, Granahan Investment Management Inc. MA, Point72 Asset Management L.P., ArrowMark Colorado Holdings LLC, Hudson Bay Capital Management LP, Opaleye Management Inc., and Rubric Capital Management LP.
View insider buying and selling activity for Kiniksa Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $11.30.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals has a market capitalization of $778.43 million. The company earns $-161.38 million in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

Kiniksa Pharmaceuticals employs 168 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

Where are Kiniksa Pharmaceuticals' headquarters?

Kiniksa Pharmaceuticals is headquartered at CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 448081896257 or via email at [email protected].